Stay updated with breaking news from Cellular Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Itolizumab was associated with high clinical response rates at Day 15 and 29Responders were able to taper steroids by 70% at Day 29 and 99% at Day 169Itolizumab being evaluated in pivotal Phase 3 EQUATOR study in first-line acute graft-versus-host diseaseLA JOLLA, Calif.--(BUSINESS WIRE)--$EQ #GVHD--Equillium, Inc...
– Three oral presentations showcase clinical evidence for Orca Bio’s promising pipeline of early- and late-stage high-precision cell therapies –– Orca-T demonstrated high relapse-free survival in recipients with fully matched donors and early potential in patients with mismatched donors –– Orca-Q showed improved gra...
NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
/PRNewswire/ -- Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company, today announced that it has been selected by the American Society for...
_on_a_T-cell_is_binding_to_a_molecule_on_a_cancer_-_Alpha_Tauri_3D_Graphics_M1_dc8762afeaee4937ad644739f274c7a5-620x480.jpg)
Adding a molecular anchor to the key protein used to recognize cancer in cellular immunotherapies can make the treatments significantly more effective.